Search alternatives:
factor » factors (Expand Search)
Showing 441 - 460 results of 19,518 for search '(complement OR implement) factor', query time: 0.22s Refine Results
  1. 441

    Correlation between serum complement C3 levels and cognitive dysfunction in patients with end-stage renal disease by Wu Si-yang, Zhang Jin, Wang Ying, Zhang Pei, Qi Xiang-ming, Wu Yong-gui

    Published 2022-07-01
    “…ObjectiveTo explore the correlation between complement level of C3, other risk factors and cognitive dysfunction in patients with end-stage renal disease (ESRD).MethodsFrom July 2019 to July 2021, medical records and laboratory examinations were collected from 92 ESRD patients. …”
    Get full text
    Article
  2. 442
  3. 443
  4. 444
  5. 445

    Acceptability, feasibility, and factors affecting implementation of a gender-sensitivity training for HIV providers and staff in Uganda: a mixed methods, quasi-experimental controlled pilot trial by K M. Sileo, R K. Wanyenze, A Anecho, R L. Luttinen, K Weston, B Mukasa, S C. Mukama, S H. Vermund, S L. Dworkin, J F. Dovidio, B S. Taylor, T S. Kershaw

    Published 2025-05-01
    “…Conclusions This study underscores the acceptability and feasibility of a gender-sensitivity training program for HIV providers; further evaluation of the program is warranted. Identified factors influencing implementation can inform enhancements to gender-focused training initiatives to improve the quality of HIV services and enhance client engagement and health outcomes. …”
    Get full text
    Article
  6. 446
  7. 447

    Drug-resistant epilepsy associated with peripheral complement decreases and sex-specific cytokine imbalances: a pilot study by Nicole Pinzon-Hoyos, Yibo Li, Monnie McGee, Nicholas P. Poolos, Nicola Marchi, Amy L. Brewster

    Published 2025-02-01
    “…We identified DRE-associated complement decreases, including reduced levels of C1q, Factor H, C4, C4b, C3, and C3b/iC3b, as well as elevated bFGF. …”
    Get full text
    Article
  8. 448

    Randomized phase I trial outcomes show safe and sustainable inhibition of classical and lectin complement pathways by empasiprubart by Inge Van de Walle, Laura Bracke, Heidi Gytz Olesen, Tonke van Bragt, Stéphanie Cadour, Phillip De Decker, Giorgia Ciurlia, Erwin Pannecoucke, Emma K. Persson, Olivier Van de Steen, Xinghong Leng, Gregers Rom Andersen, Domenica Gandini, C. Erik Hack

    Published 2025-08-01
    “…Empasiprubart is a humanized recycling monoclonal antibody that inhibits both pathways by binding to the CCP2 domain of complement factor 2 (C2), an interaction that is dependent on both Ca2+ and pH. …”
    Get full text
    Article
  9. 449

    Impact of preoperative complement-dependent cytotoxicity crossmatch on postoperative outcomes in kidney transplant recipients: A retrospective analysis by Chonghe Xu, Siqi Xie, Meiyi Lu, Wei Xu, Mei Zhu

    Published 2025-04-01
    “…However, delayed graft function rate was highest in the complement-dependent cytotoxicity of 5%–10% group. The source of donor kidneys was the most important factor influencing delayed graft function, and a larger cohort with a longer follow-up period may be needed to verify the tendency.…”
    Get full text
    Article
  10. 450

    Dynamic Complement Protein Changes in Aqueous Humor and Plasma of Patients With Retinal Vein Occlusion During Ranibizumab Treatment by Guo T, Zhao Y, Liang S, Wang J, Liu H, Zhou Y, Xu H, Chen Z

    Published 2025-01-01
    “…The concentrations of 13 complement proteins and vascular endothelial growth factor A (VEGF-A) were measured using Luminex® × MAP® technology.Results: During ranibizumab treatment, a reduction in the levels of C1q (p < 0.001), C2 (p = 0.030), C4 (p = 0.001), C4b (p = 0.026), C3b/iC3b (p < 0.001), C5 (p = 0.007), C5a (p = 0.005), CFD (p = 0.022), CFH (p < 0.001), and CFI (p < 0.001) in AH was observed. …”
    Get full text
    Article
  11. 451
  12. 452
  13. 453
  14. 454
  15. 455
  16. 456
  17. 457
  18. 458
  19. 459

    Research on promotion of implementation of clinical practice guidelines(I):the status of implementation and promotion strategies by Xu-Hui LI, Qiao HUANG, Yong-Bo WANG, Si-Yu YAN, Mu-Kun CHEN, Kuang GAO, Yi-Bei SI, Jing GUO, Wen-Bin HU, Ying-Hui JIN

    Published 2021-12-01
    “…Af-fected by factors such as low operability, single form of dissemination and application, not timely update, and lack of implementation tools and implementation evaluation tools, the implementation of clinical practice guidelines is still insufficient. …”
    Get full text
    Article
  20. 460

    Exploring meso- and macro-level contextual factors associated with inequalities in program adoption during statewide scale-up of TransformUs Primary, a whole-school physical activi... by Elly Ganakas, Jo Salmon, Jiani Ma, Karen E. Lamb, Lisa Barnett, Adrian Bauman, Amanda Telford, Nicola D. Ridgers, Anna Timperio, Harriet Koorts

    Published 2025-08-01
    “…Abstract Background Contextual influences on program implementation exist across micro (individual), meso (organization), and macro (government/environment) system levels, yet macro factors are less frequently explored in implementation research. …”
    Get full text
    Article